XSpray announces positive data from dog studies with their novel formulation strategy for PKIs.
XSpray Announces Major Advance in the Formulation of Challenging Oral Protein Kinase Inhibitors (PKI)October 10th, 2012
XSpray will be the technology provider and Cerbios will be the API manufacturer.
The SEK 2.3 million grant from Vinnova will be used to expand the company’s nanoparticle technology.
US Patent and Trademark Office has granted patent.
Providing customers with high quality particulate manufacturing meeting US and EU regulatory standards.
The Company has doubled both its personnel and lab space in order to meet growing interest.
Expanded service offering now includes sophisticated solid state characterization and analysis capabilities.
New appointment supports development plans as pharma companies begin evaluating RightSize™ technology.
GMP Manufacture using RightSize™ Manufacture Technology will enable supercritical fluid production of pharmaceuticals.
New V.P Appointment Supports the development of SCF RightSize™ Manufacture Technology.